About this Series

*Current Topics in Behavioral Neurosciences* provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats.

With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The *Behavioral Neurosciences* series focuses on “translational medicine” and cutting-edge technologies. Preclinical and clinical trials for the development of new diagnostics and therapeutics as well as prevention efforts are covered whenever possible.

More information about this series at http://www.springer.com/series/7854
Drug abuse and addiction are persistent problems in modern society, and an alarming new trend is the nonmedical use of so-called “designer drugs” or “legal highs,” more formally known as “new psychoactive substances” (NPS). By definition, NPS are drugs of abuse that are not controlled by the 1961 Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which might pose a public health threat [1]. The chemical structures of many NPS are based on compounds extracted from the biomedical or patent literature, whereas others are analogs of illicit drugs or prescribed medications. In all cases, the substances are engineered to evade existing drug control laws. At the present time, there are NPS designed to mimic most major types of abused drugs – stimulants (e.g., bath salts), cannabinoids (e.g., spice), and hallucinogens (e.g., NBOMes). NPS produce subjective effects resembling those of their progenitors, but life-threatening adverse effects are well established and include tachycardia, hyperthermia, agitation, psychosis, violent behavior, coma, and even death. Most NPS are synthesized by Asian companies and are marketed for worldwide distribution via the Internet. The United Nations Office of Drugs and Crime (UNODC) reported that between 2008 and 2015, more than 600 NPS were identified by 102 countries and territories, and this number is expected to rise [2]. NPS represent a serious global public health threat, since there is no quality control in their manufacturing or packaging, and their biological effects are unknown when they first emerge into the recreational drug marketplace.

The purpose of this book is to provide the most up-to-date knowledge about the neuropharmacology, structure-activity relationships, and toxicology of NPS. The initial idea for the volume was based on a symposium entitled, “Bath salts, spice and related designer drugs: the science behind the headlines,” held at the 2014 annual meeting of the Society for Neuroscience, in Washington DC [3]. The number of contributors for the book grew from the original symposium participants to include an international panel of experts in the field of NPS. Eighteen peer-reviewed chapters provide a rich source of information about the neurobiological effects of synthetic cathinones, cannabinoids, and hallucinogens. The topics
presented range from molecular mechanisms of action to behavioral effects and include preclinical and clinical findings. The collective data demonstrate that NPS can produce effects that are similar to the drugs they intend to mimic. However, higher potency, enhanced efficacy, and idiosyncratic metabolism can render certain NPS much more dangerous than traditional drugs of abuse. The editors are indebted to each of the principal authors, and their coauthors, who committed time and expertise to craft seminal chapters for the book; we are also grateful to Springer publishing for guidance and support throughout the publication process. Our understanding of NPS is only just beginning, yet we hope this volume provides useful information to scientists, clinicians, law enforcement agencies, and policymakers who are engaged in responding to the growing phenomenon of NPS. We believe that disseminating unbiased scientific information about NPS is a key first step for increasing public awareness about the risks associated with these substances, thereby decreasing demand and avoiding potential harms.

Baltimore, MD, USA 
Richmond, VA, USA 
Research Triangle Park, NC, USA

Michael H. Baumann 
Richard A. Glennon 
Jenny L. Wiley

References

# Contents

The Growing Problem of New Psychoactive Substances (NPS) .......................... 1  
Bertha K. Madras

Structure-Activity Relationships of Synthetic Cathinones ............................. 19  
Richard A. Glennon and Malgorzata Dukat

Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells ........................................ 49  
Linda D. Simmler and Matthias E. Liechti

Electrophysiological Actions of Synthetic Cathinones on Monoamine Transporters .................................................. 73  
Ernesto Solis, Jr.

Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs ............................. 93  
Michael H. Baumann, Mohammad O. Bukhari, Kurt R. Lehner, Sebastien Anizan, Kenner C. Rice, Marta Concheiro, and Marilyn A. Huestis

Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure–Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs ............................. 119  
S. Stevens Negus and Matthew L. Banks

Reinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm ............................................. 133  
Lucas R. Watterson and M. Foster Olive

Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration .............................................. 145  
Shawn M. Aarde and Michael A. Taffe
The Affective Properties of Synthetic Cathinones: Role of Reward and Aversion in Their Abuse .......................................................... 165
Heather E. King and Anthony L. Riley

MDMA, Methylone, and MDPV: Drug-Induced Brain Hyperthermia and Its Modulation by Activity State and Environment ............... 183
Eugene A. Kiyatkin and Suelynn E. Ren

Neurotoxicology of Synthetic Cathinone Analogs .......................... 209
Mariana Angoa-Pérez, John H. Anneken, and Donald M. Kuhn

Combination Chemistry: Structure–Activity Relationships of Novel Psychoactive Cannabinoids ..................................................... 231
Jenny L. Wiley, Julie A. Marusich, and Brian F. Thomas

Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites ......................................................... 249
Sherrica Tai and William E. Fantegrossi

Tripping with Synthetic Cannabinoids (“Spice”): Anecdotal and Experimental Observations in Animals and Man ......................... 263
Torbjörn U.C. Järbe and Jimit Girish Raghav

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens ................................................................. 283
Adam L. Halberstadt

Clinical Pharmacology of the Synthetic Cathinone Mephedrone ...... 313
Esther Papaseit, José Moltó, Robert Muga, Marta Torrens, Rafael de la Torre, and Magí Farré

Application of a Combined Approach to Identify New Psychoactive Street Drugs and Decipher Their Mechanisms at Monoamine Transporters ................................................................. 333
Felix P. Mayer, Anton Luf, Constanze Nagy, Marion Holy, Rainer Schmid, Michael Freissmuth, and Harald H. Sitte

NPS: Medical Consequences Associated with Their Intake ............... 351
Fabrizio Schifano, Laura Orsolini, Duccio Papanti, and John Corkery